TY - JOUR
T1 - Clonal architecture of chronic myelomonocytic leukemias
AU - Itzykson, Raphaël
AU - Kosmider, Olivier
AU - Renneville, Aline
AU - Morabito, Margot
AU - Preudhomme, Claude
AU - Berthon, Céline
AU - Adès, Lionel
AU - Fenaux, Pierre
AU - Platzbecker, Uwe
AU - Gagey, Olivier
AU - Rameau, Philippe
AU - Meurice, Guillaume
AU - Oréar, Cédric
AU - Delhommeau, François
AU - Bernard, Olivier A.
AU - Fontenay, Michaela
AU - Vainchenker, William
AU - Droin, Nathalie
AU - Solary, Eric
N1 - Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Genomic studies in chronic myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MPN/MDS, have identified common mutations in genes encoding signaling, epigenetic, transcription, and splicing factors. In the present study, we interrogated the clonal architecture by mutation-specific discrimination analysis of single-cell-derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/MDS. This analysis reveals a linear acquisition of the studied mutations with limited branching through loss of heterozygosity. Serial analysis of untreated and treated samples demonstrates a dynamic architecture on which most current therapeutic approaches have limited effects. The main disease characteristics are early clonal dominance, arising at the CD341/CD382 stage of hematopoiesis, and granulomonocytic differentiation skewing of multipotent and common myeloid progenitors. Comparison of clonal expansions of TET2 mutations in MDS, MPN, and CMML, together with functional invalidation of TET2 in sorted progenitors, suggests a causative link between early clonal dominance and skewed granulomonocytic differentiation. Altogether, early clonal dominance may distinguish CMML from other chronic myeloid neoplasms with similar gene mutations.
AB - Genomic studies in chronic myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MPN/MDS, have identified common mutations in genes encoding signaling, epigenetic, transcription, and splicing factors. In the present study, we interrogated the clonal architecture by mutation-specific discrimination analysis of single-cell-derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/MDS. This analysis reveals a linear acquisition of the studied mutations with limited branching through loss of heterozygosity. Serial analysis of untreated and treated samples demonstrates a dynamic architecture on which most current therapeutic approaches have limited effects. The main disease characteristics are early clonal dominance, arising at the CD341/CD382 stage of hematopoiesis, and granulomonocytic differentiation skewing of multipotent and common myeloid progenitors. Comparison of clonal expansions of TET2 mutations in MDS, MPN, and CMML, together with functional invalidation of TET2 in sorted progenitors, suggests a causative link between early clonal dominance and skewed granulomonocytic differentiation. Altogether, early clonal dominance may distinguish CMML from other chronic myeloid neoplasms with similar gene mutations.
UR - http://www.scopus.com/inward/record.url?scp=84877928684&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-06-440347
DO - 10.1182/blood-2012-06-440347
M3 - Article
C2 - 23319568
AN - SCOPUS:84877928684
SN - 0006-4971
VL - 121
SP - 2186
EP - 2198
JO - Blood
JF - Blood
IS - 12
ER -